Metformin May Mimic Biological Benefits of Strenuous Exercise for Prostate Cancer Patients Facing Mobility Limits

New research shows metformin raises Lac-Phe, a molecule tied to exercise, in prostate cancer patients. Learn how this drug supports metabolism during treatment.

By: AXL Media

Published: Apr 6, 2026, 8:50 AM EDT

Source: Information for this report was sourced from University of Miami Miller School of Medicine

Bridging the Gap Between Physical Activity and Pharmacological Support

Regular exercise is widely recognized as a cornerstone of health maintenance during oncological care, yet many patients facing advanced prostate cancer find such activity impossible due to debilitating fatigue or treatment side effects. Researchers at the Sylvester Comprehensive Cancer Center have identified that metformin, a common medication for type 2 diabetes, may activate the same internal energy-management signals usually triggered by a workout. According to the study published in EMBO Molecular Medicine, the drug increases a specific molecule that helps regulate appetite and weight, providing a potential metabolic safety net for patients who are physically unable to remain active.

The Molecular Mechanics of the Lac-Phe Signal

The focal point of this transdisciplinary research is a naturally occurring metabolite known as N-lactoyl-phenylalanine, or Lac-Phe. This substance is typically generated when lactate, produced during physical exertion, fuses with the protein building block phenylalanine. Historically, Lac-Phe has been noted for its tendency to spike after intense exercise, coinciding with improvements in weight control and energy balance. The Sylvester team, led by Dr. Marijo Bilusic, observed that metformin independently elevates these levels in prostate cancer patients to a degree that approximates the results of strenuous physical labor, even in the total absence of patient movement.

Counteracting the Metabolic Strain of Hormone Therapy

Prostate cancer care often involves hormone-based treatments that, while effective at suppressing tumors, frequently disrupt the patient's metabolism. These therapies are notorious for contributing to insulin resistance, cardiovascular risk, and significant weight gain. By elevating Lac-Phe, metformin may offer a way to mitigate these systemic burdens. Dr. Bilusic, a genitourinary medical oncologist, noted that seeing a metabolic signal mirroring intense exercise was striking, particularly for those whose symptoms limit their mobility. This chemical mimicry does not replace the need for movement but offers a supplemental pathway to maintain strength and resilience during the most demanding phases of care.